<DOC>
	<DOCNO>NCT01009931</DOCNO>
	<brief_summary>This phase II trial study side effect well give tetradecanoylphorbol acetate together dexamethasone choline magnesium trisalicylate work treat patient relapsed refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Phase II Study TPA Plus Dexamethasone &amp; CMT Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Choline magnesium trisalicylate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria Must histologically document relapsed/refractory AML standard therapy demonstrate curative palliative potential . ECOG performance status 02 . Must 18 year old . Estimated life expectancy &gt; 1 month . Laboratory data : total bilirubin ≤ 1.5 x upper limit normal unless due Gilbert 's syndrome serum creatinine ≤ 2.0 mg/dl AST ≤ 3.0 x upper limit normal Cardiac ejection fraction &gt; 40 % FEV1.0 &gt; 50 % predict Prior therapy : &gt; 3 week since chemotherapy , biological therapy radiation ; anticipate maximum hematological improvement since last dose chemotherapy . ( Concurrent hydroxyurea administration allow control WBC count , platelet count , symptom ) . No active infection . Negative pregnancy test woman childbearing potential . No uncontrolled psychiatric illness medical illness principal investigator feel compromise patient 's tolerance study medication . Must provide informed consent . Exclusion Criteria Patients allergy proton pump inhibitor , require GI prophylaxis ; salicylate exclude . Pregnant lactate woman Age &lt; 18 year . Because dose adverse event data currently available use TPA alone combination dexamethasone patient &lt; 18 year age , child exclude study eligible future pediatric Phase II combination trial . The effect TPA develop human fetus unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation 10 week . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Should female partner participant study become pregnant suspect pregnant study , PI study available provide advice medical/obstetric care/referral female partner . Patients active CNS involvement ( documented radiographic lesion and/or malignant cell CSF ) exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . Patients treatment investigational drug within last 30 day prior enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Relapsed AML</keyword>
	<keyword>Refractory AML</keyword>
</DOC>